mardi 25 février 2020

Onco Actu du 25 février 2020


1.1.1 BIOLOGIE - GÉNOME - MÉTASTASES



Extra chromosomes in cancers can be good or bad [Cold Spring Harbor Lab]










3.1 PRÉVENTION - TABAC



Philip Morris drew up plan for £1bn tobacco transition fund [The Guardian]











England off track to meet government's 2030 smoke-free target [Cancer Research UK]











England predicted to miss target of becoming smoke-free by 2030 [The Guardian]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Vaping battle heats up as FDA deadline looms [Washington Post]











The EVALI and Youth Vaping Epidemics — Implications for Public Health [NEJM]










3.3 PRÉVENTION - VACCINS



A single-dose HPV vaccine would have a big impact on cancer prevention [STAT]










Women can be protected from cervical cancer – so why aren't we doing it? [The Guardian]











4.1 DÉP., DIAG. & PRONO. - PROSTATE



Debating the Value of PSA Prostate Screening [NY Times]










4.5 DÉP., DIAG. & PRONO. - COLORECTAL



Should polygenic risk scores be used in risk-stratified colorectal cancer screening? [CDC Genomics and Precision Health]











4.9 DÉP., DIAG. & PRONO. - SEIN



Mammograms not helpful in women 75 and older, study finds [Reuters]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Repurposing Astellas' and Novartis' leukemia drugs in resistant lung cancer [Fierce Biotech]











Leukemia drugs hold promise for treatment-resistant lung cancer [University of Toronto]











Targeting hibernating breast cancer cells in the lung could reduce secondary cancers [The Francis Crick Institute]











5.10 TRAITEMENTS - ESSAIS



Lung-MAP: A five-year recap on the first master protocol trial in cancer research [The Cancer Letter]










5.12 IMMUNOTHÉRAPIES



Real-World Data Validation of Association Between Immunoregulatory Molecules Expression and Targetable Cancer Genes [ESMO]











5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS



Antigen-based metric could better predict which patients benefit from immunotherapy, study says [STAT]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Hidden Costs of CAR T-Cell Therapy [Medscape]











5.12.6 IMMUNOTHÉRAPIES - AMM



Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer [BMS]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



Study: Inflammation Caused by Radiation Can Drive Triple-Negative Breast Cancer [ChristianaCare]










5.2 PHARMA



Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer [Takeda]











U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer [GSK]











FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer [Roche]











5.2.3 PHARMA - ÉCONOMIE



Sanofi to create massive standalone API producer by melding six sites in Europe; IPO to come [Fierce Pharma]











Sanofi to start pharmaceutical ingredients company, which it says may avert future shortages [STAT]











5.2.6 PHARMA - BIOTECH



Say goodbye to Tocagen, struggling brain cancer biotech to reverse merge with Forte Biosciences [EndPoints]











5.4 TRAITEMENTS - ECONOMIE



In a nod toward pharma, ICER makes deal to access real-world evidence [Biopharma Dive]











Drug pricing review group signs deal with Aetion for patient data [Reuters]











6.1 OBSERVATION



Study examines reasons why colon cancer is more deadly in pediatric-age and young adult patients than adults age 25 and over [American College of Surgeons]











6.10 POLITIQUES



UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System [Xconomy]











6.7.1 IA/BIOINFORMATIQUE



A Turing test for artificial intelligence in cancer [Nature Cancer]